1st Quarter - Report

ASSOCIATION FOR ACCESSIBLE MEDICINES for ASSOCIATION FOR ACCESSIBLE MEDICINES

Firm
Client
Income
—
Expenses
$434,495
Expense method
C: businesses, Internal Revenue Code section 162(e)

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

FDA Congressional Appropriations Any other matter that relates to access to generic drugs Generic Drug User Fees Funding for FDA, including but not limited to: any proposal relating to funding for the Office of Generic Drugs FY2009 Presidential Budget Request

LobbyistCovered position, as disclosed
GARY HEIMBERG —
KATHLEEN D JAEGER —
LISA LAYMAN New Bryan and John Chafee; Budget Analyst, CBO
JASON R MONEY —

Contacted: Patent & Trademark Office (PTO); Treasury, Dept of; HOUSE OF REPRESENTATIVES; SENATE; U.S. Trade Representative (USTR); Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC); White House Office; Congressional Budget Office (CBO); Federal Trade Commission (FTC); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS)

Copyright/Patent/Trademark CPT

Patent Reform, including but not limited to: S.1145 and H.R.1908 Patent Settlements/Reverse Payments, including but not limited to: S.316, H.R.1432, and H.R.1902 Special 301 Report International Intellectual Property Issues Any other matter that relates to access to generic drugs

LobbyistCovered position, as disclosed
GARY HEIMBERG —
KATHLEEN D JAEGER —
LISA LAYMAN New Bryan and John Chafee; Budget Analyst, CBO
JASON R MONEY —

Contacted: White House Office; HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO); Federal Trade Commission (FTC); Treasury, Dept of; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); U.S. Trade Representative (USTR); Congressional Budget Office (CBO); Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); SENATE

Bills named: H.R. 1432 (110th), H.R. 1908 (110th), H.R. 1902 (110th), S. 316 (110th), S. 1145 (110th)

Medicare/Medicaid MMM

Medicaid Reimbursement All provisions relating to access to generic medicine Medicaid Rebates The Deficit Reduction Act of 2006: all provisions relating to prescription drug reimbursement Any other matter that relates to access to generic drugs

LobbyistCovered position, as disclosed
GARY HEIMBERG —
KATHLEEN D JAEGER —
LISA LAYMAN New Bryan and John Chafee; and Budget Analyst, CBO
JASON R MONEY —

Contacted: HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); Congressional Budget Office (CBO); Federal Trade Commission (FTC); White House Office; Patent & Trademark Office (PTO); U.S. Trade Representative (USTR); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Treasury, Dept of; Health & Human Services, Dept of (HHS); SENATE

Trade (domestic/foreign) TRD

Free Trade Agreements, including but not limited to: Colombia, Panama, Korea Special 301 Report Any matters related to international activities with regrad to access to generic medicines

LobbyistCovered position, as disclosed
GARY HEIMBERG —
KATHLEEN D JAEGER —
LISA LAYMAN New Bryan and John Chafee; Budget Analyst, CBO
JASON R MONEY —

Contacted: U.S. Trade Representative (USTR); Commerce, Dept of (DOC); White House Office; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Patent & Trademark Office (PTO); SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Treasury, Dept of; Federal Trade Commission (FTC); Congressional Budget Office (CBO)

Pharmacy PHA

Generic Biologics, including but not limited to: S.623, S.1505, S.1695, H.R.1038, H.R.1956, and H.R.5629 Prescription Drug Safety Food and Drug Administration Amendments Act of 2007 (H.R.3580): any parts relating to access to generic drugs and the impact and marketing of prescription drugs Citizen Petitions, including but not limited to: S.25 and S.1088 Counterfeit Drugs/Import Safety/Pedigree Authorized Generics including but not limited to: S.438 and H.R.806 Electronic Prescribing (E-Prescribing), including but not limited to: S.2408 and H.R.4296 Prescription Drug Importation/Re-Importation Any other matter that relates to access to generic drugs

LobbyistCovered position, as disclosed
GARY HEIMBERG —
KATHLEEN D JAEGER —
LISA LAYMAN New Bryan and John Chafee; and Budget Analyst, CBO
JASON R MONEY —

Contacted: Health & Human Services, Dept of (HHS); White House Office; Congressional Budget Office (CBO); SENATE; Treasury, Dept of; HOUSE OF REPRESENTATIVES; Federal Trade Commission (FTC); Commerce, Dept of (DOC); Food & Drug Administration (FDA); Patent & Trademark Office (PTO); Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR)

Bills named: S. 623 (110th), S. 1088 (110th), H.R. 806 (110th), H.R. 5629 (110th), S. 25 (110th), H.R. 4296 (110th), S. 2408 (110th), S. 1695 (110th), S. 438 (110th), H.R. 1956 (110th), H.R. 3580 (110th), H.R. 1038 (110th), S. 1505 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.